Start the conversation
Shares of a promising biotech we recommended back in February 2013 - jumped as much as 27% to a three-month high of $14.20 yesterday after the company said a new cancer drug met its main goal in a midstage clinical trial.
Its shares backtracked a bit as the day progressed but still closed 17.6% higher for the session. These shares have advanced 361% since we first told you about them. The stock has generated a peak gain of 456%, making it one of the 31 recommendations we've made to you that have doubled or better since we launched Private Briefing in August 2011. (More on that later...)
This is premium content for Private Briefing subscribers only.